Case Study: Nitrosamine Risk Assessment for a Proton Pump Inhibitor Seeking ANDA Approval
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a […]
Case Study: NDSRI Quantification at Ultra-Low Levels for a Drug with a 10 ng/day Acceptable Intake Limit
Introduction NDSRI Quantification at Ultra-Low Levels requires advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies capable of detecting mutagenic impurities at
Case Study: Nitrosamine Risk Assessment and Testing for a Combination Oral Solid Dosage Form with Multiple APIs
Introduction: Nitrosamine Risk Assessment for Combination Oral Solid Dosage Forms is particularly important when a pharmaceutical product contains two or
Nitrosamine Leachables Testing: From Risk Assessment to Confirmatory LC-MS/MS Analysis
Introduction Nitrosamine Leachables Testing is a comprehensive analytical and regulatory process used to evaluate pharmaceutical packaging and drug delivery systems
Nitrosamine Leachables Testing: From Risk Assessment to Confirmatory LC-MS/MS Analysis Read More »
Nitrosamine Testing for Antidepressants and SSRIs: NDSRI Risk Assessment and CRO Services
Introduction Nitrosamine Testing for Antidepressants and SSRIs is a specialized analytical and regulatory process designed to detect, quantify, and control
Headspace GC-MS for Volatile Nitrosamine Analysis: Method Development and Regulatory Acceptance
Introduction Headspace GC-MS for Volatile Nitrosamine Analysis is a sophisticated and highly selective analytical technique widely employed to identify and
Nitrosamine Testing for Antibiotics and Beta-Lactam APIs: Structural Risks and Analytical Approach
Introduction Nitrosamine Testing for Antibiotics and Beta-Lactam APIs is a specialized analytical mandate focused on the detection, identification, and quantification
Case Study: Nitrosamine Root Cause Investigation and Control Strategy for a Sartan-Class API Manufacturing Site
Introduction: Nitrosamine Root Cause Investigation for Sartan APIs has become a defining requirement across pharmaceutical manufacturing following the global recalls
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method?
Introduction The critical operational and compliance difference between a nitrosamine screening method and a confirmatory method is primarily defined by
What Is the Difference Between a Nitrosamine Screening Method and a Confirmatory Method? Read More »
ICH M7 vs. FDA Nitrosamine Guidance: Regulatory Framework Alignment and Key Differences
Introduction: When comparing ICH M7 vs FDA Nitrosamine Guidance, both share the same objective — protecting patients from potentially carcinogenic
ICH M7 vs. FDA Nitrosamine Guidance: Regulatory Framework Alignment and Key Differences Read More »